Dosing also diverged from the approved label. Regorafenib's standard dose (RSD) is an average daily dose of 160 mg for 21 days of a 28-day cycle, yet more than a quarter of patients (26.5%) were ...
However, the risk of these rare cancers is not enough to dissuade prescribing CAR T-cell therapy for CLL, explains Kerry Rogers, MD, The James.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results